|
Q-460
|
Thursday, October 16, 2025 |
With regard to the Vaccine Injury Support Program: (a) how many claims have been submitted to the program since its launch in 2021, broken down by year and province; (b) how many claims have been fully processed, how many are still pending, and what is the average processing time; (c) what is the average and median compensation awarded, and what is the total amount of compensation awarded to date; (d) what steps, if any, has the government taken to address claim backlogs; (e) what was the total value of the government's contracts with Oxaro Inc. for the administration of the Vaccine Injury Support Program, including any amendments, broken down by contract date; (f) what performance targets or service standards are included in the contracts with Oxaro Inc.; (g) how has the government evaluated whether Oxaro Inc. has met those targets; and (h) what penalties or corrective measures are in place if Oxaro Inc. fails to meet its obligations? |
Answered |
Wednesday, December 3, 2025 |
|
Q-459
|
Thursday, October 16, 2025 |
With regard to the government's response to adverse events following vaccination in relation to reproductive health (pregnancy, menstrual disorders, maternal outcomes): (a) does the Vaccine Injury Support Program, the Public Health Agency of Canada or Health Canada maintain any statistics on claims or medical reports submitted by pregnant persons (either who were pregnant at the time of vaccination or subsequently) whose alleged injury involves obstetric, fetal, neonatal, or reproductive outcomes (such as miscarriage, stillbirth, preterm birth, congenital anomalies, etc.), and, if so, what are the numbers, broken down by year, and how many such claims have been accepted or rejected; (b) does the Vaccine Injury Support Program or the Public Health Agency of Canada collect or monitor claims involving significant menstrual changes (heavy bleeding, amenorrhea, menstrual irregularities) temporally related to vaccination, and, if so, how many and what percentage of such claims have been accepted or declined; (c) if no such monitoring or claims exist in relation to (b), will the government commit to retrospective review of menstrual and reproductive adverse effects, and include them in an expanded Vaccine Injury Support Program mandate or bonus coverage; (d) what medical causality framework is used to adjudicate claims involving reproductive or menstrual injuries (what standard of evidence, what expert review, how is confounding risk handled); (e) has the government commissioned or examined any internal or external studies (Canadian or international) into vaccine-associated menstrual changes or adverse pregnancy outcomes that might inform eligibility, compensation policy, or claim adjudication guidelines, and, if so, what are the titles, findings, and government responses for each; and (f) does the government claim there is insufficient scientific evidence linking vaccination to menstrual or reproductive harm, and, if so, will it commit to funding a Canadian long-term cohort study or registry to monitor menstrual and reproductive outcomes post-vaccination (with transparent periodic reporting)? |
Answered |
Wednesday, December 3, 2025 |
|
Q-395
|
Wednesday, October 1, 2025 |
With regard to the government's decision to make persons with sole mental illness eligible for
medical assistance in dying: (a) what evidence has the government reviewed to demonstrate that irremediability in mental illness can be reliably predicted;
(b) what studies, data, or expert consultations has the government undertaken or reviewed regarding
the long-term outcomes of patients with mental illness who may have wished to seek medical assistance in dying in the
past, but later recovered or found effective treatment, and how was this evidence weighed in the
decision to expand eligibility; (c) what consultations were undertaken with psychiatric associations, disability advocates, and Indigenous leaders prior to confirming the expansion; (d) how did the government respond to warnings from psychiatric and medical experts that suicidality is a symptom of mental illness and cannot be distinguished from eligibility for medical assistance in dying; (e) what safeguards does the government plan to implement to ensure persons with depression, post-traumatic stress disorder, or other treatable conditions are not prematurely deemed eligible for medical assistance in dying; (f) what analysis has the government conducted to assess whether such an expansion could undermine national suicide prevention strategies; and (g) how does the government plan to reconcile the expansion of medical assistance in dying with its obligations under the Federal Framework for Suicide Prevention? |
Answered |
Monday, November 17, 2025 |
|
Q-394
|
Wednesday, October 1, 2025 |
With regard to federal health funding and medical assistance in dying:
(a) how much federal funding has been allocated annually since 2016 to expand palliative care
services, in total, and broken down by province or territory; (b) how much federal funding has been allocated annually since 2016 to administer or support medical assistance in dying; (c) what measures has the government taken to track the number of medical assistance in dying requests where the applicant cited lack of access to mental health care, palliative care, or disability supports as a motivating factor;
(d) how has the government evaluated whether insufficient access to care is driving vulnerable
Canadians toward medical assistance in dying rather than recovery-oriented supports; (e) what tangible steps, with dollar figures, has the government taken to ensure that access to adequate mental health treatment, including timely psychiatric care, counselling, and community supports, is guaranteed for Canadians before medical assistance in dying is considered as an option; and (f) what measures has the government taken to track the number of medical assistance in dying requests where the applicant cited lack of access to mental health care, palliative care, or disability supports as a motivating factor? |
Answered |
Monday, November 17, 2025 |
